We're trimming a stock that has made a comeback, locking in big hard-fought profits

Jim Cramer's Charitable Trust plans to sell 150 TJX shares at about $146 each, reducing its position to 975 shares and portfolio weighting from 4.25% to about 3.7%. The trust says the stock has largely rebounded from its slide from $150 to about $123 and the sale would lock in an approximately 130% gain on shares bought in August 2022. It remains positive on TJX's response to a same-store sales slowdown at Marmaxx but is trimming the position in case the fix takes longer than expected.

Analysis

This is portfolio housekeeping, not a company catalyst: a small charitable-trust trim should not be treated as informed evidence of deteriorating fundamentals or as a meaningful source of selling pressure in TJX. The useful signal is the risk being managed—confidence in the Marmaxx recovery may be ahead of proof. If comparable-sales execution takes longer to normalize, weaker store productivity could pressure operating leverage and make the recent rebound vulnerable; the key confirmation is subsequent Marmaxx comps alongside inventory and gross-margin trends, not the seller’s realized gain.

Over the next 1–3 months, retail results and management commentary should determine whether the recovery is durable. Over 6–18 months, sustained execution would support TJX’s off-price positioning, while persistent comp or margin weakness could shift share toward other value retailers such as Ross Stores and Burlington Stores. That substitution is conditional, not established by this article. The contrarian point: investors may overread a high-profile trim as a bearish call, even though the stated driver is position concentration after a rebound. Conversely, the rebound itself is not evidence the operating issue is fully fixed. No valuation or consensus data here supports a price target or directional trade.

Key Decisions for Investors

• Do not trade TJX solely on this disclosure; it is a trust-level position adjustment, not a material company event.
• If TJX is oversized in a portfolio, consider trimming to a pre-set risk weight rather than extrapolating the seller’s timing or gain.
• Use the next results and guidance as the catalyst check: reassess if Marmaxx comparable sales remain weak or inventory/gross-margin trends deteriorate; sustained improvement would falsify the cautious execution thesis.
• Avoid a standalone short pending operating evidence. Revisit a relative-value position versus other value retailers only if TJX’s comps or margins lag persistently and the peer data confirm share capture.